Viatris Inc's (NASDAQ:VTRS) Chief Legal Officer, Brian Roman, has sold a significant portion of his stock in the company. The recent filing with the Securities and Exchange Commission revealed that Roman disposed of 89,419 shares at a weighted average price of $10.3829, totaling over $928,428.
The transactions took place on May 28, 2024, and were executed in a price range from $10.335 to $10.445 per share. Following the sale, Roman's remaining stake in the company consists of 67,723 shares of common stock. This move by a key executive at Viatris Inc. is notable to investors keeping an eye on insider activities.
Viatris Inc., based in Canonsburg, Pennsylvania, operates in the pharmaceutical preparations industry. The company, which has its roots as Upjohn Inc before the name change in 2019, is incorporated in Delaware and has established itself as a key player in the sector.
Investors and stakeholders in Viatris can request detailed information about the exact number of shares sold at each price within the range provided, as indicated in the filing's footnotes. This transparency offers a clearer picture of the transaction's specifics.
The filing was signed on behalf of Brian Roman by Kevin Macikowski, by power of attorney, on the same day of the reported transactions. As the market processes this information, the stock's performance and insider sentiment will continue to be of interest to those following Viatris Inc.
InvestingPro Insights
In light of the recent insider stock sale by Viatris Inc's (NASDAQ:VTRS) Chief Legal Officer, Brian Roman, it's worth considering additional insights that could shed light on the company's financial health and market position. According to InvestingPro data, Viatris boasts a substantial market capitalization of $12.37 billion. The adjusted P/E ratio for the last twelve months as of Q1 2024 stands at 9.76, which may suggest a potentially undervalued stock in comparison to earnings. Moreover, the company offers a compelling dividend yield of 4.62%, rewarding investors with a consistent return on investment.
Adding to the financial data, InvestingPro Tips highlight several key aspects that investors should consider. Viatris' management has been actively engaged in share buybacks, signaling confidence in the company's value. Additionally, the company is not only a prominent player in the Pharmaceuticals industry but also expects net income growth this year. These factors combined present a narrative of a company with strong fundamentals and a positive outlook, despite the recent insider sale.
For investors seeking a deeper dive into Viatris Inc.'s financial metrics and strategic positioning, there are additional InvestingPro Tips available. With an InvestingPro subscription, users can access a total of 10 tips for Viatris, offering a comprehensive analysis of the company's performance and potential investment opportunities. To enhance your investing strategy, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
Given the current metrics and the expected profitability this year, as per analyst predictions, stakeholders may find these insights valuable in reassessing their investment stance on Viatris Inc. in the wake of insider trading activity.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.